Glow Peptide Dosage Chart: GHK-Cu, BPC-157, TB-500

No standard dose for the Glow stack has been established. No trial has tested the three-peptide blend, and no regulator has reviewed a ratio for it. So this glow peptide dosage chart does something different from the seller charts you have probably seen: it shows what a Glow vial contains, what the published studies on each peptide actually used, and where the evidence stops. A licensed provider sets the dose. The chart does not.

One line of disclosure before the numbers. PeRx does not sell a Glow SKU. KLOW is the provider-prescribed stack that contains the same three peptides plus KPV, and it is what a PeRx provider considers when someone asks for Glow. If you are still working out what the Glow peptide is Read nextGLOW Peptide: What It Is and What Is in the VialGLOW is not a peptide. It is a nickname for three of them, GHK-Cu, BPC-157 and TB-500, sold together in one vial, and the name carries no standard recipe. We looked at what the sellers ranking for the term actually list, sorted the claimed benefits by how strong the evidence behind each one is, and laid out what a prescribing clinic dispenses when someone asks for GLOW. Short version: we do not sell it, and you may not need it.Read article , that guide covers the name and the vial. This page stays on the dosing question.

What Is the Glow Peptide Stack?

The Glow stack is three peptides: GHK-Cu Explore PeRxGHK-CuThe Skin Rejuvenation PeptideView peptide , a copper-binding tripeptide from the skincare literature; BPC-157 Explore PeRxBPC-157The Body Protection CompoundView peptide , the fifteen-amino-acid gastric fragment most injury protocols are built around; and TB-500, a synthetic fragment related to thymosin beta-4. The name came from social media and seller pages, not from a chemist, and it describes the skin result GHK-Cu is marketed for. It is a nickname for a combination, the way Wolverine is a nickname for BPC-157 plus TB-500.

There are two ways to run it. Separate vials keep each peptide adjustable on its own. A single blended vial fixes the proportions at manufacture; the common research-market listing is a 70 mg vial of roughly 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500. Some marketing adds NAD+ Explore PeRxNAD+The Cellular Energy CoenzymeView peptide ; it is not one of the three and this page leaves it out. One rule applies throughout: nearly all of the data are laboratory and animal studies, the human data on the individual peptides are limited, and there are no human data on the combination.

Glow Peptide Dosage Chart: Ratios by Compound

The chart has two parts because the question has two parts. Table 1 is what a standard Glow vial contains, a manufacturing fact. Table 2 is what the published studies on each peptide used, with the route and dose context quoted from the source. Neither is a dose for you. A dosage chart for a prescribed product is a label written by a pharmacy for one patient; a chart for a nickname can only describe the ingredients and the research.

Read the amounts as contents, not doses. A 70 mg vial is the whole supply, spread across however many injections a protocol calls for, and no study has tested 70 mg of anything in this combination. The percentages show what you are mostly holding: by weight, a Glow vial is mostly copper peptide.

KLOW

The three Glow peptides plus KPV, in one vial that ships fully reconstituted and ready to use. A licensed provider prescribes KLOW at PeRx after an eligibility check, a state-licensed 503A pharmacy compounds it, and each lot is tested independently for potency, sterility, endotoxins and pH before it ships.

The label states the concentration and the prescribed dosing instructions arrive with the vial, so there is no ratio arithmetic to do at home. Compounded KLOW is not an FDA-approved drug.

GHK-Cu, BPC-157, TB-500 and KPV in one ready-to-use vial, dosed by the provider.

Check eligibility

Glow Stack Dosage: What the 5:1:1 Ratio Means

A blended vial holds the three peptides in a 5:1:1 ratio by weight, and that ratio travels with every drop. Whatever amount you draw contains five parts GHK-Cu to one part BPC-157 to one part TB-500. That is the whole arithmetic, and it has one consequence people miss: you cannot raise or lower one component without moving the others by the same factor. A blend is a single ingredient with three names on the label.

The ratio itself is a manufacturer's choice. Seller pages call 5:1:1 proven or optimal; no trial has tested it or any other ratio, and the likeliest reason it exists is that the peptides are sold in 50 mg and 10 mg units. It is also a weight ratio, not a molecular one. GHK-Cu is three amino acids at about 340 daltons and BPC-157 is fifteen at about 1,400, so 50 mg of GHK-Cu holds roughly twenty times as many molecules as 10 mg of BPC-157. Whether that matters for glow peptide dosage is unknown, because nobody has measured it.

Separate vials and a blend trade against each other. Separate vials let each peptide run on its own schedule, which is how PeRx handles GHK-Cu alongside the BPC/TB-500 Explore PeRxBPC/TB-500The Ultimate Recovery ComboView peptide pair, at the cost of more injections. A blend means one injection and one fixed ratio, for people whose goals line up with all three. Which fits a given patient is a clinical judgment, made by a provider after reviewing the intake.

Glow Stack vs Glow Blend vs KLOW vs Wolverine

Three nicknames sit on the same three peptides, and a fourth ingredient separates one of them. The table keeps the components straight. The GLOW vs KLOW vs Wolverine Read nextGLOW vs KLOW vs Wolverine Stack: Which One?Three nicknames, four peptides, one recurring confusion. GLOW is GHK-Cu plus BPC-157 plus TB-500. KLOW is GLOW with KPV added. The Wolverine stack is BPC-157 and TB-500 on their own. Here is what each name actually contains, which goal each one fits, what a prescribing clinic dispenses in their place, and why an $80 research vial and a $349 pharmacy vial are not the same product.Read article comparison goes through which goal fits which, and the Wolverine stack Read nextWolverine Stack: BPC-157 and TB-500, ExplainedThe wolverine stack is two peptides, BPC-157 and TB-500, run together for injury recovery. This guide covers where the comic-book name came from, what each peptide contributes, what the research honestly supports, the side effects and open questions, what forum reports get right and wrong, and how the prescribed single-vial version differs from buying two research vials.Read article guide covers the two-peptide pair on its own.

What PeRx prescribes is KLOW, not a Glow product. The PeRx formulation, as the catalog states it, is 3 mg BPC-157, 10 mg GHK-Cu, 3 mg KPV and 3 mg TB-500 per mL in a 5 mL vial. That is a different ratio from the 5:1:1 listing: GHK-Cu is still the largest component, but it sits at roughly 3:1:1 against the repair peptides, and KPV joins them in equal measure. A provider decides whether KLOW fits at all; for someone whose only goal is skin, single-peptide GHK-Cu is often the more sensible start. The KLOW dosage Read nextKLOW Peptide Dosage: Chart, Frequency, CycleNearly every KLOW dosage chart online describes an 80 mg research vial that someone mixes at their kitchen table. The KLOW a physician actually prescribes is a different product with different math. This is the dosing as written on the PeRx prescription: units on the syringe, days per week, weeks per cycle, and what the gray-market charts get wrong.Read article page runs the per-peptide arithmetic, and the KLOW guide Read nextKLOW Peptide: The Complete GuideKLOW packs four repair peptides into one prescribed vial: BPC-157, GHK-Cu, KPV, and TB-500. This guide covers what each one contributes, what the research actually supports, what a six-week cycle looks like in practice, and how the prescribed vial differs from the research-site blends that dominate search results.Read article covers the blend from the top.

Dosing Context for Each Compound

What follows are summaries of published studies, not instructions. Each section links to the single-compound dosage page, where the prescribed product and the conventions around it are laid out in full.

GHK-Cu

Most of what is known about GHK-Cu in people comes from creams and serums on facial skin. Those small cosmetic trials, summarized in the Pickart reviews, measured skin density, elasticity, fine lines and photodamage, and they are the source of nearly every skin claim attached to the Glow name. Injection is a different route with a different evidence base: in rats, GHK-Cu injected into wound chambers increased collagen and other matrix proteins as the concentration rose. No published trial has given GHK-Cu under the skin to people, so there is no measured absorption, half-life or blood level to aim for. When a page quotes a GHK-Cu milligram figure, ask which route it means; a topical number says nothing about an injected one. The GHK-Cu dosage chart Read nextGHK-Cu Dosage Chart: Units, Schedule, Copper MathSearch for a GHK-Cu dosage chart and you get a Reddit thread and a handful of research-vendor pages, all quoting 1 to 2 mg per injection as if a trial had set it. No trial did. The human GHK-Cu data is almost entirely topical, and the injection figures are clinic convention. This page lays out those conventions as the ranges they are, then the one dose a licensed provider actually prescribes through PeRx: 20 units, 2 mg, Monday through Friday, from a 10 mg/mL vial. Units, weekly totals, the copper arithmetic, timing and missed doses, as of October 1, 2026.Read article sets out the clinic conventions, the prescribed PeRx strength and the copper arithmetic.

BPC-157

BPC-157 has the deepest research record of the three, and almost all of it is in animals, most of it from one laboratory in Zagreb. The rat Achilles study that anchors the tendon claim gave BPC-157 intraperitoneally once daily at 10 micrograms, 10 nanograms or 10 picograms per kilogram, a range spanning a millionfold, and reported better biomechanical and functional recovery across it. The cell work showed tendon fibroblasts migrating more as the concentration rose. In people, the evidence amounts to small uncontrolled pilots: a retrospective review of 16 patients given knee injections, whose summary states no dose, and a two-person intravenous safety study at 10 mg and 20 mg. Neither tells you what a subcutaneous dose does. The BPC-157 dosage chart Read nextBPC-157 Dosage Chart: mL, Units, and CostA BPC-157 dosage chart is only as good as the concentration it assumes, and most of the ones online assume a vial you mixed yourself. PeRx BPC-157 ships ready to use at a fixed 3 mg/mL, so this chart works every time: micrograms to insulin-syringe units to mL in one table, plus the mcg-vs-mg trap, capsule dosing, course length, and what a month costs, as of August 31, 2026.Read article covers the prescribed product and the conventions around it.

TB-500

TB-500 is the research-market name for a synthetic fragment of thymosin beta-4, a 43-amino-acid protein found in nearly every human cell. The distinction matters for dosing, because the human studies used the full-length protein, not the fragment. In healthy volunteers, intravenous thymosin beta-4 at 42 to 1,260 mg, as a single dose and then daily for 14 days, was well tolerated in a safety study, and in two phase 2 trials a topical gel sped healing of venous stasis and pressure ulcers. In rats, thymosin beta-4 on the wound or given intraperitoneally raised re-epithelialization by 42 to 61 percent over saline. None of that is a subcutaneous dose of the TB-500 fragment, for which no controlled human dosing data exist. The TB-500 dosage Read nextTB-500 Dosage: Protocols, Units, Cycle LengthSearch for a TB-500 dosage and you get loading phases, maintenance weeks, and milligram figures that no human trial has ever tested. This page lays out where those numbers come from, why the clinical literature cannot settle them, and what the numbers look like when TB-500 arrives as a prescribed blend at a fixed concentration: 20 units on an insulin syringe, Monday through Friday, six weeks on and six off, as of September 8, 2026.Read article page and the BPC-157 and TB-500 dosage chart Read nextBPC-157/TB-500 Dosage Chart: Units, mg, CycleThe prescribed BPC-157/TB-500 blend has one concentration and one dose, and every number on this page follows from those two facts. Draw 20 units and you get 0.6 mg of each peptide. Here is the full arithmetic: the dosage chart, units on an insulin syringe, per-day and per-week totals, how the capsules dose differently, and what a month actually costs.Read article cover the fragment as prescribed, and the peptide dosage chart Read nextPeptide Dosage Chart: Doses for Every PeRx PeptideEvery peptide PeRx prescribes, in one dosing reference: route, typical dose, and frequency, with a link to the detailed chart for each. Plus the syringe math that turns milligrams into units, and the reason charts from different pharmacies never quite agree.Read article puts every PeRx product on one page.

Glow Protocol: Cycle Length and Timelines

Protocols described online run the Glow stack in cycles of about 8 to 12 weeks with breaks of 2 to 4 weeks. That pattern comes from practitioner reports and forum consensus, not from trials. No study has run the blend for any length of time, so nobody has measured whether a break is needed, how long it should be, or what happens when the cycle ends. A prescribed product carries its own schedule on the label, set by the provider and the pharmacy; the KLOW dosage Read nextKLOW Peptide Dosage: Chart, Frequency, CycleNearly every KLOW dosage chart online describes an 80 mg research vial that someone mixes at their kitchen table. The KLOW a physician actually prescribes is a different product with different math. This is the dosing as written on the PeRx prescription: units on the syringe, days per week, weeks per cycle, and what the gray-market charts get wrong.Read article guide explains the cycle on the PeRx KLOW label.

Two things keep the windows honest. The skin outcomes with human support were measured in cream studies, so a glow peptide dosage schedule built on them is borrowing from a different route. And the windows describe the order in which changes are reported, not a promise that they arrive. The GHK-Cu before and after Read nextGHK-Cu Before and After: Results, Week by WeekMost GHK-Cu before-and-after pages show a serum result and describe an injection, or describe an injection and cite nothing. The human results that exist come from 12-week trials of creams on the faces of a few dozen women. No published trial has measured what injected GHK-Cu does to anyone. This guide keeps those facts apart from what patients on the injectable protocol report, lays out the week-by-week picture with its sources attached, and shows you how to photograph and track your own skin so the comparison means something.Read article post covers the one component with human skin data, and the KLOW before and after Read nextKLOW Peptide Before and After: What Changes, WhenEvery KLOW before-and-after page online promises glowing skin by week four and a healed tendon by week eight. No published study has tracked anyone on the four-peptide blend, so those schedules are assembled from single-peptide research and user reports. Here is what people actually describe, in what order, how strong the evidence behind each change is, and why PeRx shows no photos.Read article post lays out the week-by-week picture for the four-peptide blend.

Glow Peptide Side Effects and Who Should Avoid It

With no safety study of the combination, what is known comes from reports on the individual peptides, and those are counts of complaints, not measured rates. The common ones: temporary redness or irritation at the injection site, a brief local swelling, the short sting copper solutions are known for, mild headache, short-term fatigue or nausea in the first week, and occasional lightheadedness after a dose. Long-term human safety data for the three together do not exist. For the component-by-component picture, including the NSAID caution on every BPC-157 product, see KLOW side effects Read nextKLOW Side Effects: Four Peptides, One Honest AnswerKLOW combines BPC-157, GHK-Cu, KPV, and TB-500 in one vial, which means its side-effect profile is really four profiles plus the honest admission that nobody has studied the combination. Here is what patients actually report, what each component brings to the safety picture, the copper arithmetic, and who gets screened out before a vial ever ships.Read article .

The angiogenesis question deserves its own sentence. BPC-157 promotes new blood-vessel growth in animal models, which is part of how it is thought to help injured tissue heal and the reason for the cancer precaution. Whether it matters in people at any dose is unknown. Report anything unusual to the prescriber rather than waiting out a course, and treat swelling of the face or throat, trouble breathing or a racing heartbeat after an injection as an emergency. The copper peptide's regulatory status is covered in is GHK-Cu FDA approved Read nextIs GHK-Cu FDA Approved? Regulatory Status (2026)No. GHK-Cu has never entered clinical trials for injection. But it has been used in topical skincare for over 40 years, and the Broad Institute's Connectivity Map revealed it modulates over 4,000 human genes. GHK-Cu is one of the most extensively researched peptides at the molecular level, with zero clinical trial investment. Here is why.Read article .

Why Dose Accuracy and Testing Matter

With three compounds in one vial, the ratio has to be right, not just the purity. A vial that is 98 percent pure peptide but short on one component is a different product from the one on the label, and the difference is invisible: the result is simply inconsistent, and the person using it concludes the stack does not work or needs more. Purity testing catches contaminants. Potency testing of each component catches a ratio that drifted, and a licensed pharmacy with batch testing is how a prescribed product answers this.

A certificate of analysis should show the identity and potency of each peptide against its label claim, plus sterility and endotoxin results for an injectable, under a lot number that matches the vial. How to read a peptide COA Read nextHow to Read a Peptide COAA Certificate of Analysis is the lab report behind a peptide vial. Learn to read one line by line: identity, purity, net peptide content, sterility, and endotoxin. Then learn the red flags that separate a real prescription COA from the screenshot a gray-market vendor pastes into a product page.Read article walks through each line. PeRx compounds through a state-licensed 503A pharmacy and tests every lot independently for potency, sterility, endotoxins and pH; how PeRx tests its peptides describes what that covers.

A prescribed vial arrives ready to use with no reconstitution needed. The label states the concentration, the prescribed dosing instructions come with it, and the pharmacy's storage directions are on the label: refrigerated, away from light, with the opening date noted. How to store peptides Read nextHow to Store Peptides: Fridge, Travel & Shelf LifeStoring peptides is simpler than most of the internet makes it sound, especially with PeRx. Because every vial ships fully reconstituted and ready to use, there is nothing to mix and no powder to manage. Keep it cold, keep it dark, do not freeze it. Here is the complete answer, product by product.Read article and how to inject peptides Read nextHow to Inject Peptides: Subcutaneous GuideA clear, practical walkthrough of subcutaneous peptide injections, from supply setup to sharps disposal. Written for patients new to self-injection with ready-to-use PeRx vials.Read article cover the handling side. The dose itself is the provider's, not this page's.

Getting KLOW Through a Prescription

Four steps. An eligibility check, then a licensed provider reviews your health history and goals, then a state-licensed 503A pharmacy fills the prescription if one is written, and the vial ships ready to use, with a provider check-in before each renewal. Compounded KLOW is not an FDA-approved drug; how to get peptides prescribed online Read nextHow to Get Peptides Prescribed OnlineThere is a legitimate way to get peptides prescribed through telehealth, and there is a gray market that skips the medicine entirely. This guide walks the real path step by step: the online assessment, the licensed provider who reviews it, the US compounding pharmacy that prepares your peptide, and the box that arrives ready to use. It also shows you how to spot the sites you should walk away from.Read article walks through the process. If a four-peptide blend is more than the goal calls for, the two-part route below keeps the copper peptide and the repair pair on separate prescriptions, and the peptide stacks page and the recovery peptides category show the rest of what a provider can choose from.

Glow Peptide Dosage FAQs

References and Review

The dose contexts in the chart are quoted from the studies below so that every evidence label can be checked. No study of the three-peptide combination exists as of October 2026. Regulatory statements point to the FDA-status posts for BPC-157 Read nextIs BPC-157 FDA Approved in 2026? The Honest AnswerNo. BPC-157 has never been submitted for FDA approval and has never entered formal clinical trials. It is available as a compounded medication prescribed by licensed providers. Despite being the most widely used peptide in therapy, its entire evidence base comes from preclinical research. Here is what that means and why millions of people use it anyway.Read article , TB-500 Read nextIs TB-500 FDA Approved? Parent in Phase 2 TrialsNo. TB-500 is not FDA-approved. But its parent molecule, Thymosin Beta-4, has been studied in multiple human clinical trials for wound healing and cardiac repair. RegeneRx Biopharmaceuticals ran these trials through Phase 2 before pausing development. TB-500 is the synthetic version used in compounded peptide therapy.Read article and GHK-Cu Read nextIs GHK-Cu FDA Approved? Regulatory Status (2026)No. GHK-Cu has never entered clinical trials for injection. But it has been used in topical skincare for over 40 years, and the Broad Institute's Connectivity Map revealed it modulates over 4,000 human genes. GHK-Cu is one of the most extensively researched peptides at the molecular level, with zero clinical trial investment. Here is why.Read article .

Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. View study

Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. View study

Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-2376. View study

Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. View study

Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. View study

Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13. View study

Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20-24. View study

Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. View study

Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-229. View study

Treadwell T, Kleinman HK, Crockford D, Hardy MA, Guarnera GT, Goldstein AL. The regenerative peptide thymosin beta4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann N Y Acad Sci. 2012;1270:37-44. View study